NO175964C - Analogifremgangsmåte til fremstilling av en terapeutisk aktiv, platinaholdig, makromolekylær, kompleks sammensetning - Google Patents

Analogifremgangsmåte til fremstilling av en terapeutisk aktiv, platinaholdig, makromolekylær, kompleks sammensetning

Info

Publication number
NO175964C
NO175964C NO880705A NO880705A NO175964C NO 175964 C NO175964 C NO 175964C NO 880705 A NO880705 A NO 880705A NO 880705 A NO880705 A NO 880705A NO 175964 C NO175964 C NO 175964C
Authority
NO
Norway
Prior art keywords
platinum
macromolecular
preparing
therapeutically active
complex composition
Prior art date
Application number
NO880705A
Other languages
English (en)
Norwegian (no)
Other versions
NO880705L (no
NO880705D0 (no
NO175964B (no
Inventor
Anthony J Serino
Geoffrey W Henson
David A Schwartz
Donald H Picker
Original Assignee
Johnson Matthey Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson Matthey Inc filed Critical Johnson Matthey Inc
Publication of NO880705D0 publication Critical patent/NO880705D0/no
Publication of NO880705L publication Critical patent/NO880705L/no
Publication of NO175964B publication Critical patent/NO175964B/no
Publication of NO175964C publication Critical patent/NO175964C/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Organic Insulating Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO880705A 1987-02-25 1988-02-17 Analogifremgangsmåte til fremstilling av en terapeutisk aktiv, platinaholdig, makromolekylær, kompleks sammensetning NO175964C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/018,715 US4793986A (en) 1987-02-25 1987-02-25 Macromolecular platinum antitumor compounds

Publications (4)

Publication Number Publication Date
NO880705D0 NO880705D0 (no) 1988-02-17
NO880705L NO880705L (no) 1988-08-26
NO175964B NO175964B (no) 1994-10-03
NO175964C true NO175964C (no) 1995-01-11

Family

ID=21789419

Family Applications (1)

Application Number Title Priority Date Filing Date
NO880705A NO175964C (no) 1987-02-25 1988-02-17 Analogifremgangsmåte til fremstilling av en terapeutisk aktiv, platinaholdig, makromolekylær, kompleks sammensetning

Country Status (12)

Country Link
US (1) US4793986A (da)
EP (1) EP0280474B1 (da)
JP (1) JPS63284134A (da)
AT (1) ATE96679T1 (da)
AU (1) AU596774B2 (da)
CA (1) CA1305665C (da)
DE (1) DE3885317T2 (da)
DK (1) DK96588A (da)
IE (1) IE63003B1 (da)
NO (1) NO175964C (da)
NZ (1) NZ223549A (da)
ZA (1) ZA881077B (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956454A (en) * 1984-06-27 1990-09-11 Johnson Matthey Plc Monoclonal antibody - platinum co-ordination compound complex
US4952676A (en) * 1984-06-27 1990-08-28 Johnson Matthey Plc Monoclonal antibody-platinum co-ordination compound complex
GB8806224D0 (en) * 1988-03-16 1988-04-13 Johnson Matthey Plc Platinum chemotherapeutic product
US5057301A (en) * 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
US4931553A (en) * 1988-05-11 1990-06-05 Gill Devinder S Platinum-polymer complexes and their use as antitumor agents
SU1685944A1 (ru) * 1988-06-06 1991-10-23 Институт Физической Химии Им.Л.В.Писаржевского Способ получени комплексного соединени платины (II) с высокомолекул рной н-ДНК из селезенки крупного рогатого скота марки А, обладающего противоопухолевой активностью
US5010176A (en) * 1988-11-10 1991-04-23 Eli Lilly And Company Antibody-drug conjugates
US5639624A (en) * 1989-03-14 1997-06-17 Board Of Regents Of The University Of Nebraska Monoclonal antibodies specific for metallic cations and method therefor
US5972656A (en) * 1989-03-14 1999-10-26 Bionebraska, Inc. Mercury binding polypeptides and nucleotides coding therefore
EP0463110B1 (en) * 1989-03-14 1998-01-07 Board Of Regents Of The University Of Nebraska Monoclonal antibodies for metallic cations
ATE127476T1 (de) * 1990-04-06 1995-09-15 Univ Tulane Lhrh-analoge.
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
CA2173460A1 (fr) * 1993-10-04 1995-04-13 Gilles Fillion Composes modifiant la transmission serotoninergique; applications diagnostiques et therapeutiques
EP0692252B1 (en) * 1994-06-14 2001-04-04 "Raffinerie Tirlemontoise", société anonyme: Use of a composition containing inulin or oligofructose in cancer treatment
AU2701395A (en) * 1994-06-27 1996-01-19 General Hospital Corporation, The Graft co-polymer adducts of platinum (ii) compounds
US5811510A (en) * 1995-04-14 1998-09-22 General Hospital Corporation Biodegradable polyacetal polymers and methods for their formation and use
US6111079A (en) * 1995-06-05 2000-08-29 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefore
WO1998056424A1 (en) * 1997-06-12 1998-12-17 Ml Laboratories Plc Biologically active materials
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
KR100729015B1 (ko) * 2000-01-04 2007-06-14 어섹스 팔마큐티칼스 인코포레이티드 N,o-아미도말로네이트 백금 착화합물
WO2001070685A2 (en) 2000-03-22 2001-09-27 Solulink, Incorporated Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
US6455073B1 (en) 2000-07-10 2002-09-24 Enzrel, Inc. Covalent microparticle-drug conjugates for biological targeting
US20030082102A1 (en) * 2001-06-25 2003-05-01 Court Wayne S. Radioactive platinum complexes for cancer treatment
WO2003059988A2 (en) * 2002-01-14 2003-07-24 The General Hospital Corporation Biodegradable polyketal polymers and methods for their formation and use
CA2492803C (en) 2002-07-19 2013-11-05 The General Hospital Corporation Oxime conjugates and methods for their formation and use
US7138520B2 (en) * 2003-01-13 2006-11-21 Massachusetts Institute Of Technology Coordination complexes having tethered therapeutic agents and/or targeting moieties, and methods of making and using the same
ATE507845T1 (de) 2003-09-05 2011-05-15 Gen Hospital Corp Polyacetal-arzneimittelkonjugate als freisetzungssystem
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
EP1745802A1 (en) * 2005-07-20 2007-01-24 Kreatech Biotechnology B.V. Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes
US20090148958A1 (en) * 2006-04-27 2009-06-11 Onecell Inc. Nucleotide-transition metal complex catalyst
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US20080300389A1 (en) * 2007-06-04 2008-12-04 Yang David J Metal-polysaccharide conjugates: compositions, synthesis and methods for cancer therapy
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
CL2009002167A1 (es) 2008-12-10 2010-10-15 Mersana Therapeutics Inc Formulacion farmaceutica para administracion endovenosa que comprende un compuesto derivado de conjugados de camptotecina-polimero biocompatibles y biodegradables, un agente de estabilizacion, uno o varios tampones y un tensoactivo, util para el tratamiento del cancer.
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
NL2020121B1 (en) * 2017-12-19 2019-06-26 Linxis B V Platinum-based functional moieties for preparing cell targeting conjugates
NL2020120B1 (en) * 2017-12-19 2019-06-26 Linxis B V Methods for preparing cell targeting conjugates and conjugates obtainable by said methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4385046A (en) * 1980-12-15 1983-05-24 Minnesota Mining And Manufacturing Company Diagnostic radio-labeled polysaccharide derivatives
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
IL66338A (en) * 1982-07-15 1986-03-31 Yeda Res & Dev Anti-cancer drugs comprising platinum complexed antitumor immunoglobulins
US4584392A (en) * 1982-11-10 1986-04-22 Inco Alloys International, Inc. Platinum and palladium complexes
IL67789A (en) * 1983-01-31 1986-09-30 Yissum Res Dev Co Amino-substituted malonato platinum(ii)complexes and method for their preparation
US4673754A (en) * 1983-10-14 1987-06-16 Inco Alloys International, Inc. Platinum and palladium complexes
DE3582961D1 (de) * 1984-06-27 1991-07-04 Johnson Matthey Plc Platinkoordinationsverbindungen.
IL73972A0 (en) * 1984-12-31 1985-03-31 Yeda Res & Dev Agents based on platinum compounds

Also Published As

Publication number Publication date
AU1213588A (en) 1988-09-01
ATE96679T1 (de) 1993-11-15
AU596774B2 (en) 1990-05-10
EP0280474A2 (en) 1988-08-31
DE3885317T2 (de) 1994-03-03
IE880498L (en) 1988-08-25
NO880705L (no) 1988-08-26
EP0280474B1 (en) 1993-11-03
NO880705D0 (no) 1988-02-17
NZ223549A (en) 1989-10-27
US4793986A (en) 1988-12-27
CA1305665C (en) 1992-07-28
DK96588D0 (da) 1988-02-24
DK96588A (da) 1988-08-26
NO175964B (no) 1994-10-03
EP0280474A3 (en) 1990-01-31
JPS63284134A (ja) 1988-11-21
IE63003B1 (en) 1995-03-08
DE3885317D1 (de) 1993-12-09
ZA881077B (en) 1988-08-11

Similar Documents

Publication Publication Date Title
NO175964C (no) Analogifremgangsmåte til fremstilling av en terapeutisk aktiv, platinaholdig, makromolekylær, kompleks sammensetning
LU91498I2 (fr) Etanercept et ses dérivés pharmaceutiquement acceptables.
ES478047A1 (es) Procedimiento para la obtencion de acidos 4-piridon-3-car- boxilicos.
NL7611970A (nl) Werkwijze voor het bereiden van corticoide ste- roiden, werkwijze voor het bereiden van trime- thylsiloxysteroiden, werkwijze voor het berei- den van preparaten die deze verbindingen bevat- ten, alsmede de verkregen gevormde preparaten.
FI104234B1 (fi) Menetelmä vasta-ainekonjugaattien valmistamiseksi neoplastisten sairauksien hoitoon
NL7601427A (nl) Werkwijze voor het bereiden van preparaten voor het ontbladeren van planten, alsmede gevormde ontbladeringspreparaten.
HUT41390A (en) Process for preparing 3-cyan pyridine derivatives and pharmaceutical preparations comprising the same as active substance
AU1313883A (en) Perfluorohydrocarbons as vehicles for drugs
NL175435C (nl) Werkwijze voor de bereiding van optisch aktieve aminozuurverbindingen.
EP0006614A3 (en) Pyridyl- and imidazopyridyloxypropanolamines, process for preparing the same and pharmaceutical compositions containing the same
HU177823B (en) Rodenticide composition containing n-alkyl-2,4-dinitro-6-trifluoromethyl-diphenyl-amine derivatives and process for producing the active agents
NL168880C (nl) Werkwijze voor het bereiden van bacterie-eiwit.
PT81093B (pt) Processo para a preparacao de uma composicao terapeutica para tratamento de um tumor
PT86619A (pt) Process for preparing alkylmelatonins
CS189001B2 (en) Process for preparing optically active 13,14-dehydro-11-deoxyprostaglandines
NL7613342A (nl) Werkwijze voor het bereiden van n,n'-bis-trime- thylsilylureum.
NL7902117A (nl) Werkwijze voor de bereiding van een optisch aktieve alpha-cyano-alcohol-ether.
SU542766A1 (ru) Способ автоматического управлени процессом непрерывного выращивани микроорганизмов
NL7600614A (nl) Werkwijze voor het bereiden van cyclohexeenesters, werkwijze voor het bereiden van herbicide prepara- ten, alsmede de gevormde preparaten.
NL7600776A (nl) Werkwijze voor het bereiden van preparaten voor het reguleren van de plantegroei.
NL7605503A (nl) Werkwijze voor het bereiden van preparaten voor het reguleren van de plantegroei.
PT65122A (fr) Diamino-2,4 bromo-5 chloro-6 pyrimidines utilisables comme medicaments et procede pour preparation
GB1254948A (en) Antivirial substance
NL7602860A (nl) Werkwijze voor het bereiden van 1-hydroxy 2.2.2- -trichloorethaanthionofosfonzuurdialkylesters, alsmede de toepassing daarvan als insecticiden.
AU7861575A (en) N-carbamoyl-2-cyano-2-oxyimino-acetamides as plant disease control agents